These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 16633140)

  • 1. Risperidone-related weight gain: genetic and nongenetic predictors.
    Lane HY; Liu YC; Huang CL; Chang YC; Wu PL; Lu CT; Chang WH
    J Clin Psychopharmacol; 2006 Apr; 26(2):128-34. PubMed ID: 16633140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone.
    Yamanouchi Y; Iwata N; Suzuki T; Kitajima T; Ikeda M; Ozaki N
    Pharmacogenomics J; 2003; 3(6):356-61. PubMed ID: 14610521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response.
    Reynolds GP; Yao Z; Zhang X; Sun J; Zhang Z
    Eur Neuropsychopharmacol; 2005 Mar; 15(2):143-51. PubMed ID: 15695058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. -759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment.
    Ryu S; Cho EY; Park T; Oh S; Jang WS; Kim SK; Lee D; Hong KS
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):673-7. PubMed ID: 17275977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Association of antipsychotic agent-induced weight gain with a polymorphism of the promotor region of the 5-HT2C receptor gene].
    Zhang Z; Zhang X; Yao Z; Chen J; Sun J; Yao H; Hou G; Zhang X; Reynolds GP
    Zhonghua Yi Xue Za Zhi; 2002 Aug; 82(16):1097-101. PubMed ID: 12425817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia.
    Lane HY; Liu YC; Huang CL; Chang YC; Wu PL; Huang CH; Tsai GE
    J Clin Psychopharmacol; 2008 Feb; 28(1):64-8. PubMed ID: 18204343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association analysis of serotonin receptor 7 gene (HTR7) and risperidone response in Chinese schizophrenia patients.
    Wei Z; Wang L; Xuan J; Che R; Du J; Qin S; Xing Y; Gu B; Yang L; Li H; Li J; Feng G; He L; Xing Q
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Apr; 33(3):547-51. PubMed ID: 19233240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia.
    Müller DJ; Klempan TA; De Luca V; Sicard T; Volavka J; Czobor P; Sheitman BB; Lindenmayer JP; Citrome L; McEvoy JP; Lieberman JA; Honer WG; Kennedy JL
    Neurosci Lett; 2005 May; 379(2):81-9. PubMed ID: 15823421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [No association of -1438G/A polymorphism in promoter region of 5-HT2A receptor gene with antipsychotic agent-induced weight gain].
    Mou XD; Zhang ZJ; Yao ZJ; Liu W; Zhang XR; Shi JB; Sun J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Oct; 22(5):575-6. PubMed ID: 16215954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the clinical efficacy of risperidone for untreated and treated cases of schizophrenia from various aspects.
    Himei A; Okamura T
    Psychiatry Clin Neurosci; 2005 Oct; 59(5):556-62. PubMed ID: 16194258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain.
    Popp J; Leucht S; Heres S; Steimer W
    Pharmacogenomics J; 2009 Feb; 9(1):71-7. PubMed ID: 18332898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.
    Wang L; Yu L; Zhang AP; Fang C; Du J; Gu NF; Qin SY; Feng GY; Li XW; Xing QH; He L
    J Psychopharmacol; 2007 Nov; 21(8):837-42. PubMed ID: 17715206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased plasma brain-derived neurotropic factor, not nerve growth factor-Beta, in schizophrenia patients with better response to risperidone treatment.
    Lee BH; Kim YK
    Neuropsychobiology; 2009; 59(1):51-8. PubMed ID: 19270464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse effects of risperidone and haloperidol treatment in schizophrenia.
    Yen YC; Lung FW; Chong MY
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):285-90. PubMed ID: 14751424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions.
    Correia CT; Almeida JP; Santos PE; Sequeira AF; Marques CE; Miguel TS; Abreu RL; Oliveira GG; Vicente AM
    Pharmacogenomics J; 2010 Oct; 10(5):418-30. PubMed ID: 19997080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The --1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients.
    Wang L; Fang C; Zhang A; Du J; Yu L; Ma J; Feng G; Xing Q; He L
    J Psychopharmacol; 2008 Nov; 22(8):904-9. PubMed ID: 18308786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting risperidone in stable patients with schizoaffective disorder.
    Mohl A; Westlye K; Opjordsmoen S; Lex A; Schreiner A; Benoit M; Bräunig P; Medori R
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):22-31. PubMed ID: 16144783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
    Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.